Data integrity shortcomings in drug manufacturing at a former Ranbaxy Laboratories Limited plant that the US FDA discovered nearly two decades ago thanks to help from whistleblower Dinesh Thakur led to a consent decree in 2013 that the US Food and Drug Administration has invoked anew based on inspection findings last year.
By piecing together torn, discarded records and obtaining surprising admissions from plant personnel, FDA investigators uncovered a panicked effort to hide
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?